The market for ESR1 Mutated Metastatic Breast Cancer Diagnostics was valued at US$ 58.70 million in 2022 and is projected to grow at a CAGR of 11% to reach US$ 185 million from 2023 to 2033. The market for ESR1 mutated metastatic breast cancer diagnostics is expanding as a result of rising breast cancer incidence and the …